# An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

> **NCT07392255** · PHASE1,PHASE2 · RECRUITING · sponsor: **Complement Therapeutics** · enrollment: 75 (estimated)

## Conditions studied

- Geographic Atrophy Secondary to Age-related Macular Degeneration

## Interventions

- **GENETIC:** CTx001

## Key facts

- **NCT ID:** NCT07392255
- **Lead sponsor:** Complement Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2028-05-31
- **Final completion:** 2032-06-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392255, "An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07392255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*